


- (excluding China and India), Middle East/Africa, and Latin America.
- Susceptibility testing was performed by CLSI broth microdilution and interpreted using EUCAST 2021 breakpoints. Aztreonam-avibactam was tested at a fixed concentration of 4 mg/L avibactam [1,2].
 - Isolates with a multidrug-resistant (MDR) phenotype were defined as resistant by EUCAST 2020 guidelines to ≥3 of 7 sentinel agents (amikacin, aztreonam, cefepime, colistin, levofloxacin, meropenem, and piperacillin-tazobactam) [3].



^aDashed line represents the preliminary PK/PD cutoff of ≤8 mg/L for aztreonam-avibactam.
^bPoorly visible due to low number and scale of graph: isolates with aztreonam-avibactam MIC of 8 mg/L (Enterobacterales: n=24, 0.2%; *E. coli*: n=16, 0.5%; *K. pneumoniae*: n=1, 0.02%; *E. cloacae*: n=1, 0.1%), 16 mg/L (Enterobacterales: n=13, 0.1%; *E. coli*: n=10, 0.3%; *K. pneumoniae*: n=1, 0.02%; *E. cloacae*: n=1, 0.1%), 32 mg/L (Enterobacterales: n=3, 0.03%; *E. coli*: n=2, 0.06%; *K. pneumoniae*: n=1, 0.02%) and 64 mg/L (Enterobacterales: n=2, 0.02%; *E. coli*: n=1, 0.03%; *E. cloacae*: n=1, 0.1%).

Table 1. *In vitro* activity of aztreonam-avibactam and comparator agents against MDR Enterobacterales^{a,b}

Organism/Phenotype (n) ^b	MIC ₉₀ [mg/L]/% Susceptible ^a									
	ATM-AVI		ATM		MEM		AMK		CST	
	MIC ₉₀	% S	MIC ₉₀	% S	MIC ₉₀	% S	MIC ₉₀	% S	MIC ₉₀	% S
All Enterobacterales (60,546)	0.12	NA	64	70.8	0.12	95.9	8	95.1	>8	82.1
All MDR (11,214)	0.5	NA	>128	4.4	>8	78.4	>32	76.7	>8	85.3
<i>E. coli</i> (18,475)	0.12	NA	32	71.1	≤0.06	99.4	8	96.4	0.5	99.5
MDR <i>E. coli</i> (3,460)	0.12	NA	128	1.6	≤0.06	97.1	16	85.9	0.5	98.8
<i>K. pneumoniae</i> (16,315)	0.25	NA	>128	55.4	8	88.3	8	90.6	1	95.9
MDR <i>K. pneumoniae</i> (5,407)	0.25	NA	>128	2.2	>8	65.1	>32	72.7	4	89.1
<i>E. cloacae</i> (5,099)	0.5	NA	64	63.2	0.25	96.3	4	97.0	1	94.0
MDR <i>E. cloacae</i> (871)	2	NA	>128	3.2	>8	79.4	32	84.2	4	89.3

^a% Susceptible was defined using EUCAST 2021 breakpoints. ATM-AVI, aztreonam-avibactam; ATM, aztreonam; MEM, meropenem; AMK, amikacin; CST, colistin; TGC, tigecycline. Tigecycline breakpoints are defined for *E. coli* and *C. koseri* only. NA, no breakpoints available.
^bMDR, multidrug-resistant: resistant by EUCAST 2020 guidelines to ≥3 sentinel agents (amikacin, aztreonam, cefepime, colistin, levofloxacin, meropenem, piperacillin-tazobactam); n, number of isolates.